CGEN vs RCUS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

RCUS is the larger of the two ($2.28B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 1.09). CGEN is the smaller challenger ($173.35M), also expected to post a loss next year: more room to run, but more to prove. If you believe the upside is worth bigger swings, CGEN fits (beta 2.82). If you want the steadier ride, RCUS fits (beta 1.09).

CGEN vs RCUS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCGENRCUSWhat it tells you
Market cap$173.35M$2.28BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-5.23-5.12Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta2.821.09Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range22% of range1% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.085.65How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how CGEN and RCUS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CGEN and RCUS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CGEN and RCUS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Compugen (CGEN) do?

Compugen Ltd. is a clinical-stage immuno-oncology company based in Holon, Israel, listed on Nasdaq and the Tel Aviv Stock Exchange. Its edge has always been computational: a predictive discovery platform used to find new drug targets in the immune system. That platform produced the antibodies behind its pipeline. COM701 is a first-in-class antibody against PVRIG, which Compugen develops itself. COM902, an anti-TIGIT antibody, is the source of the TIGIT arm of rilvegostomig, the PD-1/TIGIT bispecific that AstraZeneca licensed and now runs in about 12 Phase 3 trials. GS-0321 (formerly COM503), an antibody that blocks IL-18 binding protein, was licensed to Gilead in late 2024 and is in Phase 1 dose escalation.

Full CGEN guide

What does Arcus Biosciences (RCUS) do?

Arcus runs a single reportable segment out of Hayward, California with roughly 600 employees, and it has never generated revenue from product sales. Every dollar recognized since the 2018 IPO has come from research, collaboration and license arrangements, principally with Gilead Sciences and Japan's Taiho Pharmaceutical. Gilead paid $725 million in 2022 to license the anti-TIGIT program (domvanalimab and AB308), the adenosine receptor program (etrumadenant) and the CD73 program (quemliclustat), plus a further $100 million option continuation payment received in 2024. Taiho holds rights across Japan and much of Asia excluding China to five Arcus programs, exercised its casdatifan option in the fourth quarter of 2025 for $15 million, and became obligated in the second quarter of 2026 to pay a $30 million clinical milestone tied to the Phase 3 PEAK-1 study. Those payments sit in deferred revenue and are released to the income statement as Arcus performs the underlying research, so reported revenue tracks the pace of laboratory and trial work rather than any commercial activity. The portfolio itself has narrowed sharply. Gilead returned the etrumadenant license in 2025, three Phase 3 studies of domvanalimab have been stopped since December 2025, and casdatifan, which Arcus owns outright, is what remains.

Full RCUS guide

CGEN vs RCUS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • CGEN drivers: Rilvegostomig royalties at AstraZeneca; COM701 and the MAIA-ovarian readout.
  • RCUS drivers: Casdatifan carries the whole valuation; Gilead has stepped back without selling.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The biggest risk is that the TIGIT class does not work well enough. For RCUS, concentration is the central risk.

CGEN or RCUS: which should you pick?

If the story you believe is CGEN's (Rilvegostomig royalties at AstraZeneca), CGEN is the more direct way to own it; if it is RCUS's (Casdatifan carries the whole valuation), RCUS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CGEN and RCUS guides.

CGEN vs RCUS: the full fundamentals

CGEN. Traditional ratios do not describe Compugen well. The trailing P/E of ~4.7 looks cheap only because trailing revenue and profit include the ~$65 million December 2025 royalty sale to AstraZeneca; the recurring business generates ~$2 million to ~$4 million of revenue a quarter and a loss of ~$6 million to ~$8 million. The more useful lens is enterprise value: at ~$1.84 per share, the market places roughly ~$57 million on the pipeline above cash, about 2.1 times book equity. The five analysts tracked by Yahoo Finance have a mean target near $4.80 with a strong buy consensus, but for a company like this, valuation moves on trial data and partner news, not on quarterly earnings, so the cash balance and the burn rate are the figures that tend to anchor the share price between catalysts.

RCUS. Every conventional multiple here is either undefined or misleading. The ~23x trailing sales figure a screener prints at the November 20, 2026 price rests on a revenue stream management has already guided down to $65 million to $75 million for 2026, with no commercial engine behind it. The ~$1.9 billion enterprise value instead represents a probability-weighted view of casdatifan in clear cell kidney cancer, a market Arcus sizes at $5 billion to $10 billion, discounted for Phase 3 risk and for the cash the company expects to consume between now and the second half of 2028. That view has moved sharply: the market value fell from roughly $3.9 billion in August to about $2.8 billion ahead of the October 20 ARC-20 event and to about $2.3 billion by November 20, even though JPMorgan (Overweight, $41 target), William Blair (Outperform) and TD Cowen (Buy) had initiated coverage between mid-September and mid-October.

Headline figures (approximate, November 2026): CGEN shows share price ~$1.84 (Nov 20, 2026), market cap ~$174 million, revenue (ttm) ~$76 million (incl. ~$65 million one-time royalty sale); Q3 2026 ~$3.8 million, net income (ttm) ~$36 million (one-time driven); Q3 2026 loss ~$5.8 million; RCUS shows revenue (ttm) ~$100 million for the twelve months to September 30, 2026, versus $247 million in fiscal 2025 and $258 million in fiscal 2024. All of it is collaboration revenue from Gilead and Taiho; Arcus has never recorded product sales. Third-quarter 2026 revenue was ~$9 million, down ~65% from a year earlier, after $41 million in the second quarter (down 74%) and $17 million in the first., 2026 guidance and the deferred revenue behind it Management guides GAAP revenue of $65 million to $75 million for full-year 2026, which would be roughly a 70% decline from 2025; ~$67 million had been recognized through September, so the guide implies a small fourth quarter, and consensus is ~$6 million. The deferred revenue balance that feeds the line stood at $56 million at June 30, 2026 ($19 million current and $37 million noncurrent), down from $78 million at December 31, 2025 and $319 million at December 31, 2024. Remaining performance obligations were disclosed at $256 million at the end of 2025., operating expenses R&D was $113 million in the second quarter of 2026 and $235 million for the half, down from $139 million and $261 million. G&A was $24 million and $53 million against $29 million and $57 million. Full-year 2025 R&D was $523 million and G&A $110 million. Partnership reimbursements offsetting R&D fell to $36 million for the half from $71 million, and late-stage program spend came in at $111 million versus $129 million., earnings and eps Net loss of $91 million, or $0.72 per share, in the second quarter of 2026, and $219 million, or $1.74 per share, for the first half on 125.7 million weighted-average shares. The third-quarter 2026 loss was ~$128 million, or ~$1.00 per share. The trailing twelve-month loss is ~$453 million, or ~$3.64 per share. Fiscal 2025 produced a $353 million loss and fiscal 2024 a $283 million loss. Accumulated deficit stands at $1.704 billion. No P/E ratio exists and no income tax was recorded, given forecast full-year net operating losses..

The bottom line: CGEN vs RCUS

CGEN and RCUS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CGEN and RCUS exposure against your real portfolio. It is not an investment adviser.

Wondering how CGEN or RCUS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Compugen

Ask Walnut's AI anything about CGEN and see how it fits what you own.

FAQ

What is the difference between CGEN and RCUS?

+

Compugen Ltd. Arcus runs a single reportable segment out of Hayward, California with roughly 600 employees, and it has never generated revenue from product sales. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CGEN or RCUS the better stock?

+

Neither is universally better. RCUS is the larger incumbent; CGEN is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CGEN or RCUS?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CGEN and RCUS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CGEN vs RCUS?

+

CGEN: The biggest risk is that the TIGIT class does not work well enough. Roche, Merck and others discontinued TIGIT programs after disappointing late-stage results, and if rilvegostomig's Phase 3 trials follow that path, the royalty stream that underpins much of Compugen's value could shrink toward zero. Compugen also has no control over AstraZeneca's or Gilead's priorities, timelines or decisions to cut programs. COM701 is a single binary event: MAIA-ovarian, with only 62 patients, could show no meaningful benefit, and PVRIG has never been validated in a randomized trial. Rilvegostomig's first Phase 3 readout has also moved to the second half of 2027. Revenue is irregular and partner-driven, so headline profit in 2025 says little about the underlying business, which lost ~$5.8 million in Q3 2026 and ~$6 million to ~$8 million in earlier quarters. Having already sold part of its rilvegostomig royalties, Compugen has given up some upside in exchange for cash today. The stock traded at ~$1.84 on November 20, 2026, after a ~36% three-month fall, a level where Nasdaq's $1 minimum bid rule has bitten before (Compugen regained compliance in January 2024 after falling below it). As an Israeli company, it also carries currency and regional geopolitical exposure, and thin trading can make the shares move sharply on small news. Finally, if MAIA-ovarian succeeds, a larger registrational trial would cost far more than today's burn, which could mean dilution or a partnership on less favorable terms. RCUS: Concentration is the central risk. Three Phase 3 domvanalimab studies read out badly inside nine months, and Arcus itself warns in the filing that Phase 2 results were not predictive: EDGE-Gastric showed median overall survival beyond two years against Phase 3 benchmarks of 13 to 14 months, yet STAR-221 was still stopped in December 2025 for no benefit over standard of care. The same caution attaches to reading ARC-20 across into PEAK-1 and PEAK-20, and the ~50% fall in the shares over the three months to November 20, 2026 shows how far the market will reprice a single-asset company around one data event. Competitively, casdatifan enters a class Merck already occupies with belzutifan, which carries approval, a sales force and years of prescriber familiarity. On the financial side the revenue line is mechanically shrinking: deferred revenue fell to $56 million at June 30, 2026 from $78 million at year end and $319 million two years before, and partnership reimbursements that offset R&D dropped to $36 million for the half from $71 million, so reported expense can worsen even where gross spending falls. The Hercules loan is secured by substantially all of the company's assets and carries a minimum cash covenant beginning in July 2027, conditionally waived only if market capitalization exceeds a specified threshold, tying a financing covenant to the share price at the moment a data disappointment would bite hardest; the market value has already fallen from roughly $3.9 billion in August to about ~$2.3 billion. Gilead's ~24.7% position is registered and no longer accompanied by board seats, removing one reason for it to sit still. The $200 million at-the-market program and the 29.4 million shares issued during 2025 show how this company funds itself. Accumulated deficit reached $1.704 billion at June 30, 2026, the IRS is examining the 2023 tax year, and standard-of-care comparators including cabozantinib, carboplatin and oxaliplatin are flagged in the filing as difficult to source for trials.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CGEN or RCUS; figures are approximate and dated (as of November 2026). Verify current data before investing.